Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Conditions:   Recurrent Head and Neck Cancer;   Head and Neck Cancer;   Head and Neck Neoplasms;   Metastatic Cancer
Interventions:   Drug: Durvalumab;   Drug: Cetuximab
Sponsors:   Trisha Wise-Draper;   AstraZeneca
Recruiting

https://ift.tt/2Ri9jLs